Mehta M U, Venkataramanan R, Burckart G J, Ptachcinski R J, Yang S L, Gray J A, Van Thiel D H, Starzl T E
Clin Pharmacol Ther. 1986 Apr;39(4):372-7. doi: 10.1038/clpt.1986.57.
Antipyrine kinetics were studied in seven normal subjects, 10 patients with liver disease, and 13 clinically stable patients who received a liver transplant. Five patients were studied both before and after liver transplantation. Antipyrine concentrations in saliva after oral dosing were measured by HPLC. The antipyrine t1/2 was significantly longer (P less than 0.05) in patients with liver disease than in patients undergoing liver transplantation and normal subjects. Antipyrine clearance was not significantly different between patients undergoing liver transplantation and normal subjects, but it was significantly reduced (P less than 0.05) in patients with liver disease. In five patients who were studied before and after liver transplantation, there was a significant (P less than 0.05) increase in the antipyrine clearance and a marked reduction in its t1/2 after liver transplantation. These results indicate that liver transplantation improves the drug metabolizing ability of patients with liver disease and that the oxidative metabolizing capacity of the liver in clinically stable patients after liver transplantation is similar to that of normal subjects.
对7名正常受试者、10名肝病患者以及13名接受肝移植且临床状况稳定的患者进行了安替比林动力学研究。5名患者在肝移植前后均接受了研究。口服给药后通过高效液相色谱法测定唾液中的安替比林浓度。肝病患者的安替比林半衰期显著延长（P<0.05），长于肝移植患者和正常受试者。肝移植患者与正常受试者之间的安替比林清除率无显著差异，但肝病患者的安替比林清除率显著降低（P<0.05）。在5名肝移植前后均接受研究的患者中，肝移植后安替比林清除率显著升高（P<0.05），其半衰期显著缩短。这些结果表明，肝移植可改善肝病患者的药物代谢能力，且肝移植后临床状况稳定的患者肝脏的氧化代谢能力与正常受试者相似。
